拉西地平治疗原发性高血压的疗效观察  

The antihypertenstive effects and safety of lacidipine on essential hypertension

作　　者：张远慧[1] 李崇信[1] 谷小明[2] 伍卫[2] 杜志明 董吁刚[3] 黄平 黄小平 苏诚坚[5] 卢满鸿 黄洋浩[6] 何建新[6] 

机构地区：[1]第一军医大学附属南方医院心内科,广州510515 [2]中山医科大学附属第二医院 [3]中山医科大学附属第一医院 [4]广东省心血管病研究所 [5]广州医学院附属第一医院 [6]广州军区总医院

出　　处：《临床心血管病杂志》2000年第6期253-255,共3页Journal of Clinical Cardiology

摘　　要：目的 :观察拉西地平对轻、中度原发性高血压 (EH)的降压疗效及其安全性。方法 :采用自身对照开放试验方法。12 0例 EH患者 ,服安慰剂 1周后口服拉西地平 4～ 8m g(6 5 %服 4～ 6 m g)共 6周 ,不服其他降压药。观察血压、心率及各项实验室检查指标的改变。结果 :服药 6周后血压为 (144 .1± 14) / (85 .9± 7) m m Hg(1m m Hg=0 .133k Pa) ,收缩压下降 2 6 .9mm Hg,舒张压下降 15 .8mm Hg。显效 5 4例 ,有效 5 6例 ,总有效率 91.7%。有不良反应者 14例 (11.6 % ) ,主要为头晕、头痛、面红、心悸等 ,症状较轻不需停药。治疗前后各项血液生化、肝肾功能无改变。结论 :新型长效血管高选择性钙拮抗剂拉西地平对轻、中度 EH患者具有降压作用 ,不良反应少 ,耐受性好。Objective:To observe the efficacy and safety of lacidipine on mild to moderate essential hypertension.Method:By the open self control,120 essential hypertension patients (male 83,female 37;28~68 y) were enrolled in this study.After a one week placebo run in period,they received lacidipine 4~8 ( 6.1 )mg daily (4~6 mg for 65%) for six weeks without any other antihypertensive drugs.Result:After six weeks of lacidipine treatment,the average blood pressure (BP) was reduced from ( 171.0 ± 15.0 )/( 101.7 ± 7.7 ) mmHg to ( 144.1 ±14)/( 85.9 ±7)mmHg.The systolic BP was reduced by 26.9 mmHg and the diastolic BP was decreased by 15.8 mmHg. 46.7 % of patient was considered to be effective lowering of their BP,another 45% of patient was considered to be more effective.The tolol effective rate was 91.7 %.14 patiants ( 11.6 %) suffered from side effect (dizziness,headache,flush and palpitation) of this drug,but their symptoms were mild and it was unnecessary to withdraw the drug.Heart rate no changed.The biochemical index,liver and kidney function of all patients had no change.Conclusion:Lacidipine had better antihypertentive effect on mild to moderate essential hypertension patients.It′s side effect was scarce but the tolerance was quite good.

关 键 词：拉西地平 高血压 药物疗法 安全性 

分 类 号：R544.105[医药卫生—心血管疾病] R972.4[医药卫生—内科学]